Navigation Links
New Evidence Published in Muscle and Nerve on Measuring 6-Minute Walk Distance in Duchenne Muscular Dystrophy
Date:8/26/2013

. The other publication analyzes the baseline data from all DMD patients in the same Phase 2b study. The study comprised a 6-week screening period and a 48-week blinded study drug treatment period. Patients were randomized 1:1:1 to receive: ataluren at either high- or low-dose or matching placebo, daily for 48 weeks. Evaluations were performed at screening, baseline, and every 6 weeks for 48 weeks.

There were 174 randomized DMD patients included in the study. All patients screened and randomized were males, ranging in age from 5 to 20 years. Nonsense mutations were distributed across the span of the 79 exons of the dystrophin gene, with no mutational hotspots identified, and represented all three types of premature stop codons. Test-retest reliability was determined using the baseline and screening values for all endpoints. Concurrent validity and MCIDs were determined using pre-treatment data.

About Duchenne Muscular Dystrophy (DMD)
Primarily affecting males, Duchenne muscular dystrophy (DMD) is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of skeletal, diaphragm, and heart muscles. Patients with Duchenne muscular dystrophy, the more severe form of the disorder, lose the ability to walk as early as age 10 and experience life-threatening lung and heart complications in their late teens and twenties. There are an estimated 34,000 patients with DMD in the United States and Europe and approximately 13 percent of all DMD cases are caused by nonsense mutations in the dystrophin gene. More information about DMD is available through the Muscular Dystrophy Association (www.mdausa.org), Parent Project Muscular Dystrophy (www.parentprojectmd.org), Action Duchenne (www.actionduchenne.org), United
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
2. Publication of PrEP Trial Data Provides Clear Evidence that PrEP Works for Men and Women
3. 90 Presentations at Leading Radiation Oncology Meeting Demonstrate the Breadth and Depth of Clinical Evidence for Accuray Technologies
4. Annai Systems And ThoughtWorks Develop Evidence Engine For The Clearity Foundation To Individualize Options For Treatment Of Ovarian Cancer
5. Frost & Sullivan: Clinical Trial-based Evidence Vital to Obtain Venture Capital Funding for Wireless Patient Monitoring Technologies
6. Zynx Health Launches Unrivaled MEDITECH Integration for Evidence-based Care Plans
7. J.D. Power and Associates Reports: Evidence that Relationship Marketing Still Matters in Oncology Pharmaceutical Sales
8. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
9. New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease
10. New Data from Silences Atu027 Anticancer Trial Published at ASCO
11. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 NSHOA ... HRTX ) today announced positive, top-line results from ... evaluated the efficacy and safety of the Company,s ... ® (granisetron injection, extended release) as part ... neurokinin-1 (NK 1 ) receptor antagonist fosaprepitant and ...
(Date:6/1/2015)... YORK , June 1, 2015   ... of Open, Transparent and Connected financial marketplaces for ... Incorporated, a San Diego -based ... traded on OTCQB®, America,s only public venture market ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ...
(Date:6/1/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... new orphan drug indications, announced that it will be ... today, June 1, 2015, at 5:30 p.m. CDT (6:30 ... its Phase I/II study of VAL-083 (dianhydrogalactitol) ...
Breaking Medicine Technology:New cancer therapy study results - MAGIC Trial 2OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 2DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 3DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 4
... study findsLAS VEGAS, Feb. 25 Hispanic and African-American ... hip or knee replacement surgery, according to a new ... the American Academy of Orthopaedic Surgeons (AAOS) ... preoperative joint function than male patients across ethnic groups."Studies ...
... common orthopaedic conditionsLAS VEGAS, Feb. 25 The Kappa ... (OREF) presented four research awards to scientists who are ... at the 2009 Annual Meeting of the American ... . Award winners have been working towards new ...
Cached Medicine Technology:When to Have That Joint Replacement? 2When to Have That Joint Replacement? 3Applying Clinical Findings to the Practice of Medicine 2Applying Clinical Findings to the Practice of Medicine 3Applying Clinical Findings to the Practice of Medicine 4Applying Clinical Findings to the Practice of Medicine 5
(Date:6/1/2015)... Rio Salado College’s Dental Clinic ... adults this summer. , The clinics take place Friday, June ... p.m. at the Rio Salado Dental Clinic. The clinic is ... big goal for us is to offer services to the ... said Nikki Shipp, Clinical Coordinator for Rio’s dental hygiene. , ...
(Date:6/1/2015)... June 01, 2015 "This milestone opens ... were not previously able to buy and sell shares ... unsolicited orders and also make recommendations to clients as ... an ability to trade shares of our Company,” said ... and information requirements of OTCQB provides our investors greater ...
(Date:6/1/2015)... More than 22 million children may miss out on milk’s ... they lose access to free or reduced-price meal programs. June ... companies are on a mission to bring more nutritious milk ... , In many cases, food insecure children depend on ... bulk of their daily nutrition. Although the National School Lunch ...
(Date:6/1/2015)... 01, 2015 Carrick Brain Centers is ... on a global level. This evolutionary period includes ... Brain Centers to broaden their scope while helping more ... horizons are accompanied by a restructuring of the company’s ... Brain Centers will separate itself from Dr. Frederick Carrick ...
(Date:6/1/2015)... CA (PRWEB) June 01, 2015 This ... 2nd Annual GrowRIVERSIDE Conference: The Future of Local Food, ... The conference will assist cities in examining ... and urban agriculture infrastructure. , Organized for the city ... will feature a broad lineup of speakers ranging from ...
Breaking Medicine News(10 mins):Health News:Kids Receive Complimentary Dental Services at Rio Salado Dental Clinic 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 3Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 4Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:Carrick Brain Centers announces separation from Dr. Frederick Carrick to reflect the broader scope of impact and growth as an organization. 2Health News:Limited Tickets Available for “GrowRIVERSIDE” Conference June 11 2
... linked to urological problems, studies show , MONDAY, May ... reasons to start exercising and steer clear of smoking, ... can improve urinary health in women and sexual health ... than 2,000 Finnish women, aged 18 to 79, about ...
... ... inspiration for Pacific Northwest Salmon Bake at White House Picnic highlighting regional cuisines from around ... (PRWEB) ... Pinot Noir Celebration (IPNC) , Jason Stoller Smith will represent the Pacific Northwest region at ...
... ... medical. Dubai Podiatry Centre is leading the healthcare field in implementing new technology for patient ... to show detailed structure of the foot and ankle to patients, zooming in and rotating ... (PRWEB) May ...
... shrink bladder capacity, trigger pelvic pain, study finds , SUNDAY, ... drug ketamine, often called "Special K" by the young partygoers ... risk for pelvic pain and urinary incontinence. , The finding ... of researchers out of Hong Kong. They questioned 66 male ...
... taken another important step toward understanding just how sticking needles ... published online May 30 in Nature Neuroscience, a ... molecule adenosine as a central player in parlaying some of ... knowledge, scientists were able to triple the beneficial effects of ...
... A 17-year-long community study looking at symptoms of enlarged prostate ... that surgery for benign prostatic hyperplasia (BPH) ... from drug-based therapy, according to a new study by researchers ... the annual meeting of the American Urological Association . ...
Cached Medicine News:Health News:International Pinot Noir Celebration Guest Chef Jason Stoller Smith to Cook Famed Northwest Salmon Bake at White House Picnic 2Health News:Dubai Podiatry Centre Becomes the Gulf Region's First Clinic to Bring Apple iPads to the Healthcare Field 2Health News:Club Drug 'Special K' Could Leave Users Incontinent 2Health News:Club Drug 'Special K' Could Leave Users Incontinent 3Health News:Acupuncture's molecular effects pinned down 2Health News:Research finds surgery outperforms drug therapy in treatment of benign prostatic hyperplasia 2
... The Double Bundle PCL Guides were ... femoral tunnels necessary in arthroscopic double bundle ... placement for anterolateral and posteromedial femoral tunnel ... , ,During anterolateral tunnel placement a guide ...
... The Flexible Digital Implant offers surgeons ... for the correction of a hammertoe deformity. ... grade silicone and is designed for the ... five. The Futura FDI features an anatomic ...
... of the BioPro Toe implant is to ... pain and restore motion while leaving the ... procedure used to implant the BioPro Great ... ,The design for the great toe has ...
... Electrodes share similar characteristics with ... difference is that all of ... to assist you intraoperatively. In ... for use with either our ...
Medicine Products: